(By Balaseshan) Amgen Inc.
) said it has terminated late-stage ganitumab metastatic pancreatic cancer trial as committee saw no significant improvement in the primary endpoint.
"These disappointing results underscore the difficulty of treating pancreatic cancer, which remains a major unmet medical need," said Sean Harper, executive vice president of Research and Development at Amgen.
Amgen decided to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.
[Related -Amgen, Inc. (NASDAQ:AMGN): What Will Drive Amgen This Year?]
The GAMMA study is a randomized, multicenter, double-blind, Phase 3 trial to determine if ganitumab plus gemcitabine improves overall survival, compared to placebo plus gemcitabine, in the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.
Based on the review of a pre-planned interim analysis, the DMC concluded that the addition of ganitumab to gemcitabine is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to gemcitabine alone. There were no safety concerns raised in the DMC review of the study.
Amgen has communicated with regulatory authorities and is in the process of notifying study investigators that treatment with ganitumab should be discontinued in the GAMMA trial, as well as a separate ongoing Phase 2 trial in locally advanced pancreatic cancer.
[Related -Amgen, Inc. (AMGN) Q3 Earnings Preview: Pipeline In Focus]
Ganitumab is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF1R).
AMGN closed Wednesday's regular session down 0.25% at $81.37. The stock has been trading between $47.66 and $84.39 for the past 52 weeks.